Cargando…

Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients

OBJECTIVE: To investigate the influencing factors and prognosis of immune checkpoint inhibitor-related pneumonitis (CIP) in advanced non-small cell lung cancer (NSCLC) patients during or after receiving immune checkpoint inhibitors(ICIs). METHODS: The clinical and laboratory indicator data of 222 ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoyu, Hao, Na, Yang, Shuangning, Li, Jieyao, Wang, Liping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169751/ https://www.ncbi.nlm.nih.gov/pubmed/37182127 http://dx.doi.org/10.3389/fonc.2023.1145143

Ejemplares similares

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
por: Lin, Xinqing, et al.
Publicado: (2021)

The CURB65 score predicted 180-day mortality of non-small cell lung carcinoma patients with immune checkpoint inhibitor-associated pneumonitis: A pilot retrospective analysis
por: Lan, Fen, et al.
Publicado: (2022)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
por: Zhu, Shicong, et al.
Publicado: (2020)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy
por: Barrón, Feliciano, et al.
Publicado: (2020)

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
por: Chao, Yencheng, et al.
Publicado: (2022)

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
por: Huang, Aiben, et al.
Publicado: (2021)

Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2021)

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Dosiomics and radiomics to predict pneumonitis after thoracic stereotactic body radiotherapy and immune checkpoint inhibition
por: Kraus, Kim Melanie, et al.
Publicado: (2023)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
por: Diker, Omer, et al.
Publicado: (2023)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
por: Deng, Guiming, et al.
Publicado: (2023)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
por: Shu, Yang, et al.
Publicado: (2023)

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer
por: Han, Shuai, et al.
Publicado: (2023)

High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer
por: Tone, Mari, et al.
Publicado: (2019)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
por: Wang, Fuli, et al.
Publicado: (2023)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy
por: Saito, Satoshi, et al.
Publicado: (2021)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
por: Allen, Emily, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
por: Zhang, Qin, et al.
Publicado: (2021)

Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2020)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer
por: Asano, Yohei, et al.
Publicado: (2022)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Cui, Yanan, et al.
Publicado: (2022)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6ns854abnf2lrdapltsv2v779v